Indian J Pharm Close
 

Figure 2: (a) Rate of rise of ventricular pressure (+dp/dt, mmHg/min) and (b) rate of decrease of ventricular pressure (−dp/dt, mmHg/min) from control group (n = 8), simultaneous type 2 diabetes and renal hypertension group receiving vehicle (DM2 + HTN-Veh) (n = 8), and simultaneous type 2 diabetes and renal hypertension groups receiving oleuropein at 20 mg/kg/day (DM2 + HTN-Ole20) (n = 7), 40 mg/kg/day (DM2 + HTN-Ole40) (n = 6) or 60 mg/kg/day (DM2 + HTN-Ole60) (n = 8) at the preischemia (preisch), and at 30 and 60 min of reperfusion. Data are presented as mean ± SEM. Significant difference from the control (a; P = 0.05, b; P = 0.04, c; P = 0.02, d; P = 0.001). Significant difference from the DM2 + HTN-Veh (e = P = 0.05, f; P = 0.04, g; P = 0.01, h; P = 0.009, I; P = 0.005, J; P =0.003, k; P = 0.001). Significant difference from DM2 + HTN-Ole20 (l; P = 0.05, o; P = 0.04, m; P = 0.03, n; P = 0.01)

Figure 2: (a) Rate of rise of ventricular pressure (+dp/dt, mmHg/min) and (b) rate of decrease of ventricular pressure (−dp/dt, mmHg/min) from control group (<i>n</i> = 8), simultaneous type 2 diabetes and renal hypertension group receiving vehicle (DM2 + HTN-Veh) (<i>n</i> = 8), and simultaneous type 2 diabetes and renal hypertension groups receiving oleuropein at 20 mg/kg/day (DM2 + HTN-Ole20) (<i>n</i> = 7), 40 mg/kg/day (DM2 + HTN-Ole40) (<i>n</i> = 6) or 60 mg/kg/day (DM2 + HTN-Ole60) (<i>n</i> = 8) at the preischemia (preisch), and at 30 and 60 min of reperfusion. Data are presented as mean ± SEM. Significant difference from the control (a; <i>P</i> = 0.05, b; <i>P</i> = 0.04, c; <i>P</i> = 0.02, d; <i>P</i> = 0.001). Significant difference from the DM2 + HTN-Veh (e = <i>P</i> = 0.05, f; <i>P</i> = 0.04, g; <i>P</i> = 0.01, h; <i>P</i> = 0.009, I; <i>P</i> = 0.005, J; <i>P</i> =0.003, k; <i>P</i> = 0.001). Significant difference from DM2 + HTN-Ole20 (l; <i>P</i> = 0.05, o; <i>P</i> = 0.04, m; <i>P</i> = 0.03, n; <i>P</i> = 0.01)